AR119057A1 - Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de estos y métodos de tratamiento con dichos compuestos - Google Patents

Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de estos y métodos de tratamiento con dichos compuestos

Info

Publication number
AR119057A1
AR119057A1 ARP200101539A ARP200101539A AR119057A1 AR 119057 A1 AR119057 A1 AR 119057A1 AR P200101539 A ARP200101539 A AR P200101539A AR P200101539 A ARP200101539 A AR P200101539A AR 119057 A1 AR119057 A1 AR 119057A1
Authority
AR
Argentina
Prior art keywords
substituted
compounds
unsubstituted
isoindoline
oxo
Prior art date
Application number
ARP200101539A
Other languages
English (en)
Inventor
Frans Baculi
Katherine Northcote
Matthew D Correa
Joshua Hansen
Laurie A Lebrun
Chin Lu
- Lu Gang Chun
Mark A Nagy
Sophie Peng
Sophie Perrin-Ninkovic
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of AR119057A1 publication Critical patent/AR119057A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Reivindicación 1: Un compuesto caracterizado por la fórmula (1), o una sal aceptable desde el punto de vista farmacéutico, un tautómero, un isotopólogo o un estereoisómero de este, en donde: R¹ es C₁₋₃ alquilo o C₁₋₃ fluoroalquilo; R² es C₁₋₆ alquilo sustituido o no sustituido, C₃₋₁₀ cicloalquilo sustituido o no sustituido, heterociclilo de 3 a 6 miembros sustituido o no sustituido, C₆₋₁₀ arilo sustituido o no sustituido, o heteroarilo de 5 a 10 miembros sustituido o no sustituido; R³ es H; R⁴ es halógeno; y n es 0 - 3.
ARP200101539A 2019-05-31 2020-05-29 Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de estos y métodos de tratamiento con dichos compuestos AR119057A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962855619P 2019-05-31 2019-05-31

Publications (1)

Publication Number Publication Date
AR119057A1 true AR119057A1 (es) 2021-11-17

Family

ID=73551319

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200101539A AR119057A1 (es) 2019-05-31 2020-05-29 Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de estos y métodos de tratamiento con dichos compuestos

Country Status (17)

Country Link
US (2) US11306101B2 (es)
EP (1) EP3976595A4 (es)
JP (1) JP7496838B2 (es)
KR (1) KR20220016167A (es)
CN (2) CN114957212B (es)
AR (1) AR119057A1 (es)
AU (1) AU2020282748A1 (es)
BR (1) BR112021022758A2 (es)
CA (1) CA3136753A1 (es)
CL (1) CL2021003134A1 (es)
CO (1) CO2021015624A2 (es)
IL (1) IL288278A (es)
MX (1) MX2021014350A (es)
PE (1) PE20220569A1 (es)
SG (1) SG11202112872YA (es)
TW (1) TW202110819A (es)
WO (1) WO2020243379A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3136753A1 (en) 2019-05-31 2020-12-03 Frans BACULI Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith
CN112679421A (zh) * 2021-01-04 2021-04-20 都创(上海)医药科技股份有限公司 一种(r)-3-氯吡啶基-2-三氟乙胺盐酸盐的合成方法
AU2022207648A1 (en) 2021-01-13 2023-07-27 Monte Rosa Therapeutics Ag Isoindolinone compounds
US20220387405A1 (en) * 2021-05-06 2022-12-08 Celgene Corporation Methods of treatment with n-((r)-1-(3-chloropyridin-2-yl)-2,2,2-trifluoroethyl)-2-((s)-2,6-dioxopiperidin-3-yl)-1-oxoisoindoline-5-carboxamide
KR20240019272A (ko) * 2021-06-08 2024-02-14 항저우 글루바이오 파마수티컬 코., 엘티디. 이소인돌리논 화합물 및 이의 용도
CN115504963A (zh) * 2021-06-22 2022-12-23 苏州开拓药业股份有限公司 一种c-Myc蛋白降解剂
US20230373950A1 (en) 2022-03-17 2023-11-23 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023244815A1 (en) * 2022-06-16 2023-12-21 Monte Rosa Therapeutics, Inc. Molecular glue degraders and methods of using the same
WO2023244818A1 (en) * 2022-06-16 2023-12-21 Monte Rosa Therapeutics, Inc. Molecular glue degraders and methods of using the same
WO2024027694A1 (zh) * 2022-08-01 2024-02-08 苏州开拓药业股份有限公司 一种蛋白降解剂
WO2024120441A1 (zh) * 2022-12-07 2024-06-13 杭州格博生物医药有限公司 氧异吲哚-5-甲酰胺类化合物或其盐、溶剂合物的结晶形式或无定形形式
WO2024120438A1 (zh) * 2022-12-07 2024-06-13 杭州格博生物医药有限公司 一种固体分散体、其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030045552A1 (en) 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
US7091353B2 (en) * 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
AU2006285144A1 (en) 2005-08-31 2007-03-08 Celgene Corporation Isoindole-imide compounds and compositions comprising and methods of using the same
US8877780B2 (en) 2006-08-30 2014-11-04 Celgene Corporation 5-substituted isoindoline compounds
KR20090060314A (ko) 2006-08-30 2009-06-11 셀진 코포레이션 5-치환 이소인돌린 화합물
CN101578277A (zh) * 2006-08-30 2009-11-11 细胞基因公司 5-取代的异二氢吲哚化合物
US9499514B2 (en) 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
WO2017007612A1 (en) * 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
CA2995036A1 (en) 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Tunable endogenous protein degradation
CA3136753A1 (en) 2019-05-31 2020-12-03 Frans BACULI Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith

Also Published As

Publication number Publication date
CO2021015624A2 (es) 2022-02-28
EP3976595A4 (en) 2023-01-04
BR112021022758A2 (pt) 2022-03-22
MX2021014350A (es) 2022-02-21
CA3136753A1 (en) 2020-12-03
CN114957212B (zh) 2024-05-24
US11306101B2 (en) 2022-04-19
EP3976595A1 (en) 2022-04-06
AU2020282748A1 (en) 2021-12-09
CN114269729A (zh) 2022-04-01
US20200377512A1 (en) 2020-12-03
TW202110819A (zh) 2021-03-16
IL288278A (en) 2022-01-01
JP2022534979A (ja) 2022-08-04
SG11202112872YA (en) 2021-12-30
US20220213115A1 (en) 2022-07-07
KR20220016167A (ko) 2022-02-08
PE20220569A1 (es) 2022-04-20
WO2020243379A1 (en) 2020-12-03
CN114957212A (zh) 2022-08-30
JP7496838B2 (ja) 2024-06-07
CL2021003134A1 (es) 2022-07-01

Similar Documents

Publication Publication Date Title
AR119057A1 (es) Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de estos y métodos de tratamiento con dichos compuestos
AR114803A1 (es) Compuestos de 4-aminoisoindolin-1,3-diona sustituida, composiciones de estos y métodos de tratamiento con dichos compuestos
AR114244A1 (es) Compuestos que degradan efgr útiles en el tratamiento del cáncer
AR110405A1 (es) Compuestos
AR116604A1 (es) Inhibidores de kras g12c
AR108812A1 (es) Proceso para preparar un derivado de piridona policíclica sustituida y cristal del mismo
AR104884A1 (es) Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj
AR120029A1 (es) Compuestos heterocíclicos
AR116283A1 (es) Inhibidores del sarcómero cardíaco
AR093937A1 (es) Compuestos quimicos
AR093818A1 (es) Compuesto de 1-(bencil sustituido)piperazina sustituida
AR113929A1 (es) Compuestos heterocíclicos
CO2022008968A2 (es) Nuevos derivados de metilquinazolinona
AR097082A1 (es) Compuestos terapéuticamente activos y sus métodos de uso
AR109711A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR104880A1 (es) MODULADORES DE ROR GAMMA (RORg)
AR111494A1 (es) Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer
AR109776A1 (es) Compuestos de p2x₃ y/o p2x₂/₃ y métodos
CO2021002768A2 (es) Compuestos de 2,6-diaminopiridina
AR119376A1 (es) Compuestos heterocíclicos
AR117037A1 (es) Compuestos pirazol para el tratamiento de enfermedades autoinmunitarias
AR123241A1 (es) Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos
AR112463A1 (es) Derivados de propanamina para tratar el dolor y estados relacionados con dolor
AR116428A1 (es) Compuestos de 6-fluoro-2-metilbenzo[d]tiazol-5-ilo
AR111282A1 (es) Inhibidores de cdpk1 ii, composiciones y métodos relacionados con los mismos